These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22619293)

  • 21. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
    Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
    Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Benralizumab in a Patient Who Did Not Respond to Omalizumab.
    Bernal-Rubio L; de-la-Hoz Caballer B; Almonacid-Sánchez C; González-de-Olano D
    J Investig Allergol Clin Immunol; 2020; 30(5):378-379. PubMed ID: 32376515
    [No Abstract]   [Full Text] [Related]  

  • 24. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results.
    van den Berge M; Pauw RG; de Monchy JG; van Minnen CA; Postma DS; Kerstjens HA
    Chest; 2011 Jan; 139(1):190-3. PubMed ID: 21208879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting.
    Palgan K; Bartuzi Z; Gotz-Zbikowska M
    Int J Immunopathol Pharmacol; 2014; 27(1):109-12. PubMed ID: 24674685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
    Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
    Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis.
    Sánchez-Ramón S; Eguíluz-Gracia I; Rodríguez-Mazariego ME; Paravisini A; Zubeldia-Ortuño JM; Gil-Herrera J; Fernández-Cruz E; Suárez-Fernández R
    J Investig Allergol Clin Immunol; 2013; 23(3):190-6. PubMed ID: 23967758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.
    Gauvreau GM; Arm JP; Boulet LP; Leigh R; Cockcroft DW; Davis BE; Mayers I; FitzGerald JM; Dahlen B; Killian KJ; Laviolette M; Carlsten C; Lazarinis N; Watson RM; Milot J; Swystun V; Bowen M; Hui L; Lantz AS; Meiser K; Maahs S; Lowe PJ; Skerjanec A; Drollmann A; O'Byrne PM
    J Allergy Clin Immunol; 2016 Oct; 138(4):1051-1059. PubMed ID: 27185571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22.
    Baker DL; Peng K; Cheu M; Fischer SK
    Curr Med Res Opin; 2014 Oct; 30(10):1927-9. PubMed ID: 24960148
    [No Abstract]   [Full Text] [Related]  

  • 30. Re: Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. Curr Med Res Opin 2014;30:913-22.
    Strohner P; Becher G
    Curr Med Res Opin; 2014 Oct; 30(10):1923-5. PubMed ID: 24914579
    [No Abstract]   [Full Text] [Related]  

  • 31. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omalizumab for patients with severe and therapy-refractory atopic eczema?
    Andres C; Belloni B; Mempel M; Ring J
    Curr Allergy Asthma Rep; 2008 May; 8(3):179-80. PubMed ID: 18589835
    [No Abstract]   [Full Text] [Related]  

  • 33. Omalizumab: Anti-IgE therapy in allergy.
    Kopp MV
    Curr Allergy Asthma Rep; 2011 Apr; 11(2):101-6. PubMed ID: 21243454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
    Nayak A; Casale T; Miller SD; Condemi J; McAlary M; Fowler-Taylor A; Della Cioppa G; Gupta N
    Allergy Asthma Proc; 2003; 24(5):323-9. PubMed ID: 14619332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promising option in the prevention of idiopathic anaphylaxis: omalizumab.
    Demirtürk M; Gelincik A; Colakoğlu B; Dal M; Büyüköztürk S
    J Dermatol; 2012 Jun; 39(6):552-4. PubMed ID: 22390871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels.
    Belloni B; Ziai M; Lim A; Lemercier B; Sbornik M; Weidinger S; Andres C; Schnopp C; Ring J; Hein R; Ollert M; Mempel M
    J Allergy Clin Immunol; 2007 Nov; 120(5):1223-5. PubMed ID: 17936892
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of omalizumab in patients with food allergy.
    Rafi A; Do LT; Katz R; Sheinkopf LE; Simons CW; Klaustermeyer W
    Allergy Asthma Proc; 2010; 31(1):76-83. PubMed ID: 20167148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
    Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
    JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg.
    Lafuente I; Mazon A; Nieto M; Uixera S; Pina R; Nieto A
    Pediatr Allergy Immunol; 2014 Nov; 25(7):717-9. PubMed ID: 24902874
    [No Abstract]   [Full Text] [Related]  

  • 40. Omalizumab for treatment of allergic rhinitis.
    Vashisht P; Casale T
    Expert Opin Biol Ther; 2013 Jun; 13(6):933-45. PubMed ID: 23621175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.